Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00968110
Other study ID # Milk-01
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date March 2009
Est. completion date April 2017

Study information

Verified date September 2018
Source Boston Children’s Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot feasibility study, using Xolair pretreatment for oral milk desensitization. The major assessment will be safety, and the investigators will evaluate for any type of reaction, including allergic reactions that occur during the course of the study.


Description:

Our hypothesis is that pretreatment with anti-IgE mAb will greatly reduce the side effects and allergic reactions that occur during oral desensitization to foods and will enhance the development of oral tolerance in patients with severe milk allergy. Once desensitized to milk, children will be able to tolerate milk in a Double Blind Placebo Controlled Food Challenge.

The study will also evaluate whether Xolair provides a robust durability of tolerance once administration of Xolair is terminated. We will examine the specific immunological mechanisms that mediate oral tolerance in children undergoing oral milk desensitization

The trial will be conducted in three parts: (1) pre-treatment with Xolair for 8 weeks, (2) oral desensitization to cow's milk from weeks 9-16 and continued treatment with Xolair for 8 weeks, and (3) double blind placebo controlled food challenge to milk.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date April 2017
Est. primary completion date April 2017
Accepts healthy volunteers No
Gender All
Age group 4 Years to 18 Years
Eligibility Inclusion Criteria:

- Moderate to severe pediatric cow's milk allergy-sensitive subjects between the ages of 4-18 years old.

- Total IgE >30 kU/L

- Sensitivity to cow's milk allergen will be documented by a positive skin prick test result (see Appendix E for details) and RAST test to cow's milk, with 25 kU/L as a lower limit of eligibility. Patients who do not meet the cow's milk RAST requirement may be eligible for this study if they have a history of a moderate to severe reaction, and if they have recently failed an oral food challenge with milk ordered by their physician.

- All female subjects of child-bearing potential will be required to provide a urine sample for pregnancy testing that must be negative one week before being allowed to participate in the study.

- Subjects must be planning to remain in the study area during the trial.

- Subjects and/or their parents must be trained on the proper use of the Epi-Pen to be allowed to enroll in the study.

Exclusion Criteria:

- No absolute contraindications to allergen skin testing and/or oral ingestion of milk are known. However, the risk of serious systemic anaphylactic reactions to milk suggests a number of preexisting conditions that should be considered relative contraindications. Among those conditions are acute infections, autoimmune disease, severe cardiac disease, and treatment with beta-adrenergic antagonistic drugs (beta-blockers).

- Subjects having a history of severe anaphylaxis to milk requiring intubation or admission to an ICU, frequent allergic or non-allergic urticaria, or history consistent with poorly controlled persistent asthma.

- Total IgE > 2000 IU/mL.

- Subjects with unstable angina, significant arrhythmia, uncontrolled hypertension, chronic sinusitis, or other chronic or immunological diseases that in the mind of the investigator might interfere with the evaluation or administration of the test drug or pose additional risk to the subject e.g. gastrointestinal or gastroesophageal disease, chronic infections, scleroderma, hepatic and gallbladder disease, chronic non-allergic pulmonary disease.

- Subject with an FEV1 or PEF less than 80% predicted (moderate persistent asthma) with or without controller medication (if able to perform the maneuver) at screening, the oral desensitization visit, or food challenge visit.

- Subjects who have received an experimental drug in the last 30 days prior to admission into this study or who plan to use an experimental drug during the study.

- Subjects who are current users of oral, intramuscular, or intravenous corticosteroids, tricyclic antidepressants, or are taking a beta-blocker (oral or topical).

- Subjects routinely using medication that could induce adverse gastrointestinal reactions during the study.

- Subjects refusing to sign the EpiPen Training Form (see Appendix F).

- Pregnant or breast feeding females.

- Subjects with a history of rice and soy allergy.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
omalizumab
Dosing table established for omalizumab

Locations

Country Name City State
United States Children's Hosptial Boston Boston Massachusetts
United States Stanford Uneiversity Medical Center Stanford California

Sponsors (2)

Lead Sponsor Collaborator
Boston Children’s Hospital Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The major goal of this study is to assess the safety of Xolair in young children, and the safety of oral desensitization in patients pretreated with Xolair week 53
See also
  Status Clinical Trial Phase
Completed NCT01950533 - The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
Completed NCT02579876 - Milk Patch for Eosinophilic Esophagitis Phase 2
Completed NCT04318483 - Characteristic and Evolution of an Atypical IgE-mediated Cow Milk Allergy Form With Hands and Feet Angio-oedema
Completed NCT02317952 - Formula for Children With Cow's Milk Allergy N/A
Recruiting NCT03309488 - Basophil Activation Test to Diagnose Food Allergy
Completed NCT00328731 - Milk ALLERGY ELIMINATION THROUGH NAET® (Nambudripad's Allergy Elimination Techniques). Phase 1/Phase 2
Recruiting NCT05309772 - The Clinical Impact of the Basophil Activation Test to Diagnose Food Allergy N/A
Terminated NCT02719405 - Impact of Infant Formula on Resolution of Cow's Milk Allergy Phase 2
Completed NCT01361347 - Safety of Oral Immunotherapy for Cow's Milk Allergy in School-aged Children Phase 4
Completed NCT01157117 - OIT and Xolair® (Omalizumab) in Cow's Milk Allergy Phase 2
Active, not recruiting NCT00732654 - The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy Phase 1/Phase 2
Recruiting NCT03819556 - Swedish Study of Immunotherapy for Milk Allergy in Children N/A